-
Ciclesonide Workflows for Lung Research
2026-09-30
Ciclesonide offers a practical prodrug system for connecting lung-cell activation, glucocorticoid receptor binding, and anti-inflammatory outcomes. This guide pairs reproducible respiratory workflows with a carefully bounded comparison to emerging ERAD-engaging degradation technology.
-
AS1842856: A Translational Foxo1 Strategy
2026-09-30
A mechanism-first guide to using AS1842856 as a direct Foxo1 perturbation tool across gluconeogenesis, autophagy research, and the iron-sensitive PI3K-Akt-Foxo1 axis.
-
SU5416: VEGFR2 Workflows and PH Insights
2026-09-29
SU5416 (Semaxanib) supports controlled VEGFR2 blockade in endothelial, tumor, and vascular biology assays while also providing a useful bridge to immune-modulation studies. Its distinctive value in pulmonary hypertension research is methodological: the SU5416-hypoxia model can separate cardiopulmonary exercise limitation from later skeletal-muscle abnormalities.
-
PDHA1 Succinylation and Immune Escape in Cholangiocarcinoma
2026-09-29
This Nature Communications study identifies PDHA1 lysine 83 succinylation as a metabolic switch that increases α-ketoglutaric acid accumulation and suppresses macrophage MHC-II antigen presentation through OXGR1–MAPK signaling. The findings connect tumor-cell post-translational modification with immune escape and suggest that inhibiting succinylation may improve gemcitabine–cisplatin sensitivity, although clinical validation remains necessary.
-
Puromycin Aminonucleoside: Interpreting Renal Injury
2026-09-28
Puromycin aminonucleoside is a useful experimental tool for examining podocyte damage, proteinuria, and glomerular pathology. This article focuses on how to interpret model readouts and design stronger comparisons—not simply how to induce injury.
-
EdU Cell Proliferation Kit: Beyond S-Phase Counts
2026-09-27
The EdU Cell Proliferation Kit offers a direct colorimetric readout of DNA synthesis, but interpreting that signal requires more than counting proliferating cells. This article connects the assay to rheumatoid arthritis research and shows how to use it to test functional hypotheses without confusing association with mechanism.
-
Dihydrotestosterone: Practical Assay Workflows
2026-09-26
Dihydrotestosterone (DHT) offers a controllable way to probe androgen receptor activity, from growth-factor responses in bladder cancer cells to androgen-driven prostate models. This guide translates published findings into practical setup, workflow, and troubleshooting choices while distinguishing study-reported conditions from suggested pilot experiments.
-
Eltanexor (KPT-8602) in CRC Assay Design
2026-09-26
Use Eltanexor to test how blocking XPO1-mediated nuclear export affects Wnt/β-catenin signaling, COX-2, and colorectal tumor models—not only cell viability. A preclinical Apcmin/+ study offers a practical path from pathway assays to organoids, while clear controls and cautious dose finding help separate target-related effects from general toxicity.
-
CD47 Blocks Phagocytosis by Dephosphorylating Vav
2026-09-25
Miller and colleagues identify Vav phosphorylation as a key control point through which CD47 suppresses IgG-triggered macrophage phagocytosis, linking the inhibitory CD47–SIRPα axis to Rac-dependent target engulfment. Their imaging and pathway-perturbation results distinguish Rac-based reaching from a less frequent Rho-based sinking mode and help clarify how inhibitory signals can restrain antibody-driven clearance.
-
NU6300 Targets GSDMD Cys191 to Block Pyroptosis
2026-09-25
Jiang et al. identify NU6300 as a covalent gasdermin D inhibitor that modifies Cys191 and disrupts both GSDMD cleavage and palmitoylation. The work connects these molecular effects to reduced pyroptotic signaling in cells and protective effects in mouse models, while revealing a distinct response in NLRP3 compared with AIM2- and NLRC4-driven inflammation.
-
DEV VP26 Links Actin–Myosin II to Viral Replication
2026-09-24
A proteomic screen identified host cytoskeletal proteins associated with duck enteritis virus (DEV) VP26, with follow-up experiments highlighting MYH9 and the actin–myosin II network as contributors to viral replication. The findings connect VP26–host interactions with functional perturbation data and suggest practical ways to investigate cytoskeletal involvement in infection, while leaving the precise molecular mechanism unresolved.
-
ERAD-Engaging Chimeras for Membrane Protein Degradation
2026-09-24
Song and colleagues introduce ERAD-engaging chimeras (ERADECs), a targeted protein degradation strategy that recruits the ER-associated degradation machinery to remove transmembrane proteins. Their PD-L1 results, including SYVN1-dependent degradation and tumor suppression in vivo, suggest a route around limitations of approaches that rely on endosome–lysosome trafficking.
-
Dovitinib: RTK Perturbation Meets circRNA Biology
2026-09-23
Dovitinib (TKI-258) enables mechanistic studies of RTK signaling, apoptosis, and cancer-cell state. This article shows how to pair its pharmacologic readouts with circRHOBTB3–NONO–MAOA assays while clearly separating established evidence from translational hypotheses.
-
PTC124 and OCRL Rescue in Lowe Syndrome
2026-09-23
A translational framework for positioning PTC124 (Ataluren) alongside CRISPR correction and OCRL gene augmentation in patient-derived trabecular meshwork models of Lowe syndrome.
-
LC–MS/MS Reveals GS-441524 Prodrug Conversion
2026-09-22
A January 2026 Microchemical Journal study established an LC–MS/MS workflow for tracing conversion of the novel GS-441524 prodrug NGP-1 into GS441 across gastric, blood, hepatic, and rat in vivo systems. Its findings support a multi-compartment pharmacokinetic model in which both the parent prodrug and released GS441 contribute to exposure after administration, while also defining important limits for translation to clinical antiviral research.